805.43
price up icon0.82%   6.54
pre-market  Pre-mercato:  805.63   0.20   +0.02%
loading

Lilly Eli Co Borsa (LLY) Ultime notizie

pulisher
06:46 AM

Eli Lilly (LLY) Awaits European Approval for Alzheimer's Drug | - GuruFocus

06:46 AM
pulisher
02:43 AM

Eli Lilly and Company India launches ‘We Know Now’ obesity awareness campaign - MediaBrief

02:43 AM
pulisher
Jul 24, 2025

Eli Lilly's Trademark Suit Not 'Abuse Of Process' - Law360

Jul 24, 2025
pulisher
Jul 24, 2025

INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines - Business Wire

Jul 24, 2025
pulisher
Jul 24, 2025

A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster - Benzinga

Jul 24, 2025
pulisher
Jul 24, 2025

How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings? - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

The 3 Things That Matter for Eli Lilly Now - The Motley Fool

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly confirms date and conference call for second-quarter 2025 financial results announcement - MarketScreener

Jul 24, 2025
pulisher
Jul 24, 2025

Eli Lilly Q2 2025 Earnings Call: Key Date and Details Investors Should Know - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly completes tender offer for Verve Therapeutics shares By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly and Verve announce expiration of Verve tender offer | Eli Lilly and Company - Eli Lilly and Company

Jul 24, 2025
pulisher
Jul 24, 2025

Lilly Secures 55.7% of Verve Shares in $10.50 Cash Plus CVR Deal, Closing Set for July 25 - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Eli Lilly targets golden goose with Mounjaro launch in Korea amidst competitionCHOSUNBIZ - Chosunbiz

Jul 24, 2025
pulisher
Jul 23, 2025

Tariffs Weigh on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly, GE Vernova Surge Among Wednesday’s Market Cap Stock Movers - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly’s Phase 3 Breast Cancer Study: A Potential Game-Changer? - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly’s LY3971297 Study: A Potential Game-Changer in Obesity and Hypertension Treatment - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly’s Baricitinib Study: A Potential Game-Changer for Juvenile Arthritis - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Jim Cramer on Eli Lilly: “It Needs Breakthroughs in New Areas” - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Earnings Preview: What To Expect From Eli Lilly's Report - Barchart.com

Jul 23, 2025
pulisher
Jul 23, 2025

Eli Lilly (LLY) Collaborates on Alzheimer's Diagnostic Test with CE Mark Approval | LLY Stock News - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

Lilly to launch Mounjaro in Korea in August without reimbursement - koreabiomed.com

Jul 23, 2025
pulisher
Jul 22, 2025

BMO Capital Pounds the Table on Eli Lilly Stock (LLY) Ahead of Earnings - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

BMO Capital reiterates Eli Lilly stock rating with $900 price target By Investing.com - Investing.com South Africa

Jul 22, 2025
pulisher
Jul 22, 2025

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Better Growth Buy: Eli Lilly vs. Viking Therapeutics - The Motley Fool

Jul 22, 2025
pulisher
Jul 21, 2025

Eli Lilly (LLY) at a Crossroads: Assessing the Pullback, Earnings Catalysts, and Long-Term Growth in Diabetes, Obesity, and Alzheimer's - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo.co

Jul 21, 2025
pulisher
Jul 21, 2025

LLY Stock Quote Price and Forecast - CNN

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 20, 2025

Eli Lilly and Company (NYSE:LLY) Shares Could Be 38% Below Their Intrinsic Value Estimate - 富途牛牛

Jul 20, 2025
pulisher
Jul 20, 2025

Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey

Jul 20, 2025
pulisher
Jul 19, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

Jul 19, 2025
pulisher
Jul 18, 2025

Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly and Company - Lifespan Research Institute

Jul 18, 2025
pulisher
Jul 18, 2025

Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Eli Lilly's stock drops 3.08% to $765.51 on July 17, down 21.29% from 52-week high. - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool

Jul 18, 2025
pulisher
Jul 18, 2025

LLY Stock Price and Chart — NYSE:LLY - TradingView

Jul 18, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance

Jul 17, 2025
pulisher
Jul 17, 2025

Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com

Jul 17, 2025
pulisher
Jul 16, 2025

Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize

Jul 16, 2025
pulisher
Jul 16, 2025

Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

ELI LILLY AND COMPANY (LLY) - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC

Jul 16, 2025
pulisher
Jul 16, 2025

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener

Jul 16, 2025
drug_manufacturers_general JNJ
$169.56
price up icon 0.27%
$190.83
price up icon 0.15%
drug_manufacturers_general NVS
$117.46
price down icon 0.43%
drug_manufacturers_general NVO
$70.73
price up icon 1.00%
drug_manufacturers_general MRK
$84.11
price up icon 0.15%
Capitalizzazione:     |  Volume (24 ore):